Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06957561 | Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer(DIVON) | not yet recruiting | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 4, 2025 |
| clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06942416 | Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer | recruiting | Phase 2 | 36 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06415318 | TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer | recruiting | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 307 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06686030 | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | recruiting | Phase 2 | 150 | AkesoINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06705075 | Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE | recruiting | Phase 2 | 80 | Thomas Jefferson UniversityOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06916117 | Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC | not yet recruiting | Phase 2 | 30 | RenJi HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06917092 | QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer(QLPPEC/GOG-003) | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06257017 | Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma | recruiting | Phase 2 | 20 | Yung NAOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06493552 | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | recruiting | Phase 2 / Phase 3 | 700 | Vasgene Therapeutics, IncINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06878222 | Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC | recruiting | Phase 2 | 35 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06904573 | Probiotics in Advanced Urothelial Carcinoma(IMPROVE) | recruiting | Phase 2 | 222 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy(PRODIGY-1) | not yet recruiting | Phase 1 / Phase 2 | 500 | CHU de Quebec-Universite LavalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT06594679 | A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)(NICHOL) | recruiting | Phase 1 / Phase 2 | 73 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06882447 | A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer(QL1706) | not yet recruiting | Phase 2 | 35 | Northern Jiangsu People's HospitalOTHER | 0 | Mar 28, 2025 | clinicaltrials |
| NCT06786780 | Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids(ECCO) | enrolling by invitation | Phase 2 | 50 | Chongqing University Cancer HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04046094 | Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 12 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06890832 | A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | not yet recruiting | Phase 2 | 75 | Jina Pharmaceuticals Inc.INDUSTRY | 0 | Mar 24, 2025 | clinicaltrials |
| NCT06890858 | A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer | recruiting | Phase 2 | 20 | Zhejiang Provincial People's HospitalOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06823427 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 60 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04516616 | Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 85 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06288360 | Neoadjuvant Immunochemotherapy in PD-L1-negative LACC | recruiting | Phase 2 | 40 | Tongji HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06884345 | METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03525288 | PSMA-PET Guided Radiotherapy(PSMA-PETgRT) | active not recruiting | Phase 2 / Phase 3 | 130 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04100174 | Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy(fBTsRT) | recruiting | Phase 2 | 150 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06560112 | An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer | recruiting | Phase 2 | 172 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06093438 | Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05704621 | Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance(SOCCER-P) | recruiting | Phase 2 | 124 | Korea University Guro HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04487587 | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer(COMICE) | active not recruiting | Phase 2 | 79 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02202772 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder(CGC) | active not recruiting | Phase 1 / Phase 2 | 51 | Guarionex J. DecastroOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06818682 | Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial(RELAX) | recruiting | Phase 2 | 206 | Tata Memorial CentreOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06493370 | Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer | recruiting | Phase 2 | 48 | University of Kansas Medical CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04282356 | Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer(INTENS-IP) | recruiting | Phase 2 | 55 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05200260 | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | recruiting | Phase 2 | 220 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | recruiting | Phase 2 / Phase 3 | 526 | Bio-Thera SolutionsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06449781 | 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer(PSMA-ADJUVO) | recruiting | Phase 2 | 200 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03763253 | Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms(IP2-ATLANTA) | active not recruiting | Phase 2 | 433 | Imperial College LondonOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 4, 2025source: clinicaltrials